OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

GENMAB AS DK 1/  DK0010272202  /

Düsseldorf
06/11/2024  19:30:44 Chg. +2.30 Volume Bid19:40:27 Ask19:40:27 Market Capitalization Dividend Y. P/E Ratio
206.30EUR +1.13% 0
Turnover: 0.00		 -Bid Size: - -Ask Size: - 13.5 bill.EUR - -
GlobeNewswire 19/08 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 08/08 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 08/08 Genmab Updates 2024 Financial Guidance
GlobeNewswire 05/08 Genmab Takes Full Control of Acasunlimab Development Program
GlobeNewswire 28/06 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 21/05 Genmab Completes Acquisition of ProfoundBio
GlobeNewswire 02/05 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 30/04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 03/04 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 14/02 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 14/02 Genmab Publishes 2023 Annual Report
GlobeNewswire 09/11/2023 Major Shareholder Announcement
GlobeNewswire 08/11/2023 Major Shareholder Announcement
GlobeNewswire 07/11/2023 Genmab Announces Financial Results for the First Nine Months of 2023
GlobeNewswire 17/10/2023 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire 25/09/2023 Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire 04/09/2023 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire 24/02/2022 Notice to Convene the Annual General Meeting of Genmab A/S
GlobeNewswire 16/02/2022 Genmab Publishes 2021 Annual Report
GlobeNewswire 25/01/2022 Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
GlobeNewswire 10/11/2021 Genmab Announces Financial Results for the First Nine Months of 2021
GlobeNewswire 04/11/2021 Genmab Improves its 2021 Financial Guidance
GlobeNewswire 19/10/2021 Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire 21/09/2021 Capital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswire 20/09/2021 Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...